Date Mailed: August 6, 2003

Sheet 1 of 1

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OIPE
AUG 11 2003
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11576.70USI1	Application Number: 10/027,374
	Applicant: PATHAK	
	Filing Date: 12/21/2001	Group Art Unit: 3762

RECEIVED
SEP 15 2003
TECH CENTER 1600/2900
RECEIVED
AUG 13 2003
TECHNOLOGY CENTER R3700

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Auer, J. et al., "Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond," *Current Medicinal Chemistry*, Vol. 9, No. 20, pp. 1831-1850 (2002).

23552
PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED 3/4/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)